Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK, and PD of BLD-0409 in Healthy Volunteers
NCT04146805Phase 1Completed
- Sponsor
- Blade Therapeutics, Inc.
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Nonalcoholic steatohepatitis (NASH) and chronic liver disease (CLD) comparing BLD-0409 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events up to 56 days, Number of subjects with treatment-related changes in physical examinations up to 56 days and 9 more. Started Jan 2020; status: completed.
02
Drugs
cudetaxestat
03
Conditions
Nonalcoholic steatohepatitis (NASH)chronic liver disease (CLD)
Beyond the preview
Go deeper on NCT04146805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146805.